DIMERx to Present at BIO Investor Forum 2023
October 4, 2023Presentation will discuss the potential of DMX-101 as a Phase 2-ready non-addictive opioid for chronic pain
SAN FRANCISCO–(BUSINESS WIRE)–#BIF23—DIMERx, Inc., an advance-stage biopharmaceutical company, today announced that Nikhilesh N. Singh, Ph.D., Co-Founder and Chief Executive Officer, will present at the BIO Investor Forum 2023, being held October 17-18, 2023, in San Francisco.
Date of presentation: Tuesday, October 17, 2023
Time: 11:30 a.m.-11:43 a.m. PDT
Location: Franciscan Room D at Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco
Following the presentation, a copy will be available at www.dimerx.com.
About DIMERx, Inc.
DIMERx is a clinical-stage biopharmaceutical company focused on the development of a novel platform of first-in-class dimer therapeutics invented and engineered by founder Nikhilesh Singh, Ph.D. The company’s lead asset, DMX-101, has demonstrated safety, tolerability, and effectiveness through Phase 2 clinical development among IBS-D patients. DIMERx is currently raising Series A financing to progress the development of DMX-101 and IND-enabling research studies involving several other dimer candidates in the pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
Contacts